Aura Biosciences, Inc. (AURA) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Boston, MA, United States. The current CEO is Elisabet de los Pinos.
AURA has IPO date of 2021-10-29, 106 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $454.83M.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
